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The gene encoding PDX1 (pancreatic duodenum homeobox 1), the main transcription factor regulating the 
glucose-dependent transactivation of the insulin promoter in pancreatic β-cells, clusters with two closely related 
homeobox genes (Gsh1 and Cdx2/3), all of them belonging to the ParaHox gene family. The ParaHox gene 
evolutionary history in the vertebrate lineage involved duplications of the cluster and subsequent loss of some 
members, so that eventually, the human and murine genomes contain only 6 ParaHox genes. The crucial role of 
PDX1 in pancreas development, beta-cell formation and insulin transcription regulation has long been 
established. There is some data on CDX2/3 function in α−cells, but remarkably, nothing is known on the role of 
the other ParaHox genes, which are also expressed in the endocrine pancreas. Homeobox transcription factors 
that belong to the same family show high conservation of the homeodomain and share similar target sites and 
oligomeric partners, and thus may act redundantly, synergistically or antagonistically on the same promoters. 
Therefore, we explored the effects of the Parahox proteins (GSH1, GSH2, CDX1, CDX2/3 and CDX4) on the 
regulation of the insulin promoter in transfected α- and β- cultured cell lines at different glucose concentrations 
and compared them to those of PDX1. Noticeably, several ParaHox transcription factors are able to transactivate 
or inhibit the insulin promoter, depending on the cell type and glucose concentration, thus suggesting their 
possible participation in the regulation of similar target genes, such as insulin, either by silencing or activating 
them, in the absence of PDX1. 
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1.  INTRODUCTION 
PDX1 is a crucial pancreatic transcription factor. 
It functions both in the early commitment of the 
primitive gut to pancreatic fate and in the later 
maturation of β-cells. In the adult, PDX1 is mainly 
expressed in β-cells where it is a major transactivator 
of the insulin gene (reviewed in [1]). Notably, 
heterozygous mutations of the PDX1 gene are linked 
to a type of autosomal dominant diabetes mellitus 
known as maturity onset diabetes of the young 
(MODY4) [2]. Finely tuned regulation of the insulin 
gene transcription relies on the recognition of several 
promoter sequence motifs by a combination of 
ubiquitous and islet-specific transcriptions factors [3], 
whose characterization would contribute to our 
current understanding not only of insulin gene 
expression, but also of endocrine pancreas 
development and function (reviewed in [1, 4]). Several 
of these key cis-acting enhancer elements show a 
considerably degree of conservation among vertebrate 
species, suggesting that the regulatory mechanisms 
controlling insulin expression are evolutionarily 
conserved [5]. Among them, several key motifs are 
recognised and bound by homeodomain-containing 
proteins [6], the most relevant being the pancreatic 
duodenal homeobox-1 (PDX1) transcription factor. 
Similarly to other homeodomain transcription factors, 
PDX1 form oligomers with additional homeodomain 
proteins and trasncriptional regulators [7], acting in a 
synergistic fashion. Hence, the net activity of the 
promoter is subtly tuned by the concentration and 
function of any of the proteins in the complex, as well 
as by glucose, which regulates insulin gene 
transcription through multiple effects on several of the 
proteins in the transcription activation complex [8-13]. 
Although Pdx1 is pivotal for pancreas formation and 
insulin regulation, the knockout mouse for Pdx1 still 
maintains some insulin-producing cells, thus pointing 
to a degree of flexibility on the formation of the 
promoter complex, where other transcription factors, 
most probably with an homeodomain, could substitute 
its function (reviewed in [14]). 
The  Pdx1 gene belongs to the ParaHox gene Int. J. Biol. Sci. 2008, 4 
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cluster, an array of genes containing a Hox-like 
homeobox. This cluster includes Gsh and Cdx genes in 
addition to Pdx1. The ParaHox cluster is an ancient 
evolutionary sister group of the well-known Hox 
cluster [15]. These two gene complexes suffered 
several rounds of large genome duplications in the 
vertebrate lineage that eventually produced, in the 
case of the ParaHox genes in mammals, four syntenic 
segments. Currently, only one cluster remains fully 
intact [16], most probably because these clustered 
genes share common or interdigitated control regions 
[17]. Although the HOX cluster has been a 
long-standing paradigm, there is still controversy 
regarding the conserved structure of the clusters and 
the intriguing fact of the spatio-temporal colinearity in 
their expression patterns (reviewed in [15]). There is a 
wealth of information on the transcriptional targets of 
most HOX genes, although so far, comprehensive 
networks that encompass the HOX, the hundreds of 
potential target genes, and their interrelations is still 
lacking [18, 19]. Much less is known on the polemic 
ParaHox cluster, which has been mostly overlooked. 
This scarcity of data is probably due to several reasons: 
i) the ParaHox gene number is smaller, ii) only one of 
the clusters remained in mammals, iii) the apparent 
lack of colinearity in their expression, and iv) the 
prominent role of PDX1 in pancreas organogenesis 
and function has diverted most of the attention to 
function instead than organization. 
All ParaHox genes belong to the same family and 
share a very similar homeodomain, hence they may 
bind related or even identical target sites, as it is the 
case with other homeodomain trancription factors. 
Then, the specificity and the affinity of the binding to 
the promoter, as well as the effect (inhibition of 
transactivation) on transcription, would depend on the 
interacting partners (reviewed in [20]). Thus, 
conceivably, other ParaHox proteins could bind to 
Pdx1 targets in vivo, given that adequate partners are 
present. This has not been, to our knowledge, explored 
elsewhere. 
Besides Pdx1, not much data has been gathered 
on Parahox expression in pancreas. CDX2/3 is 
expressed in α-cells, where it binds to the glucagon 
promoter and activates its transcription [21]. In 
addition, and although this factor is not β cell-specific, 
CDX2/3 can recognise enhacer elements of the rat 
insulin I gene promoter usually bound by PDX1 
(German et al., 1992) and transactivate endogenous 
and recombinant rat insulin I and II promoters [22, 23]. 
Moreover, most studies on Cdx and Gsh transcription 
factors focus on their roles during embryonic 
development and tumorigenesis, and very scarce data 
is available on their biological function in adult tissues. 
We have recently shown that all ParaHox genes are 
expressed in the murine endocrine pancreas, in 
particular within the glucagon-secreting α-cells, except 
Pdx1, which is mainly detected in β- and δ-cells [24]. 
These results prompted us to further evaluate whether 
the ParaHox transcription factors might be involved in 
the regulation of similar target genes.  
Given that: i) all the ParaHox genes are 
evolutionary related, ii) share similar homeodomains 
and thus, may bind to similar target motifs; iii) some of 
the ParaHox genes are linked to Pdx1, retaining the 
original genomic clustering and potentially sharing 
common regulatory elements and, iv) their recently 
reported expression in endocrine pancreas, we aimed 
to evaluate the role of the ParaHox proteins as 
potential transcriptional regulators of the insulin gene, 
a s  p r o o f  o f  p r i n c i p l e .  T o  t h i s  e n d ,  w e  a n a l y s e d  t h e  
effect of Parahox gene overexpression on the 
transactivation of a luciferase reporter gene driven by 
the –600INS mouse promoter region in transiently 
transfected α- and β- pancreatic-derived mouse cells 
(αTC1 and βTC6).  
Our results show that evolutionarily related 
homeodomain transcription factors can share the same 
target and provide unexpected insights into the 
regulation of the insulin promoter by homeodomain 
proteins other than PDX1, which are also expressed in 
the endocrine pancreas. We surmise that this type of 
results may be extrapolated to other homeodomain 
transcription factors and target genes. 
2.  MATERIALS AND METHODS  
Cell culture 
The mouse βTC6 and αTC1 cell lines were 
obtained from ATCC (references CRL-11506 and 
CRL-2350, respectively), and all experiments were 
performed with cells between passage numbers 1 to 20. 
Cells were maintained following the manufacturer’s 
recommendations.  βTC6 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium with 4 mM 
L-glutamine, 1.5 g/l sodium bicarbonate, 
supplemented with 15% heat-inactivated fetal bovine 
serum, penicillin and streptomycin. αTC1 cells were 
cultured in Dulbecco’s Modified Eagle’s Medium with 
1.5 g/l sodium bicarbonate and supplemented with 15 
mM HEPES, 0.1 mM non-essential amino acids, 0.02 % 
bovine albumin serum (BSA) and 10 % 
heat-inactivated fetal bovine serum. Two different 
glucose concentrations were used: 4.5 g/l (25mM) and 
0.1 g/l (0.5 mM) depending on whether high or low 
glucose concentration was required for each 
experiment. 
DNA constructs 
It is well known that mRNA stability, Int. J. Biol. Sci. 2008, 4 
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nucleus/cytoplasma transport and even, mRNA 
translation efficiency, are related to mRNA maturation 
processes, in particular to the splicing events [25, 26]. 
Accordingly, many expression vectors designed to 
improve protein production in cultured cells include 
introns in the 5’ or 3’ UTRs. Alternatively, the 
expression of coding sequences derived from genomic 
amplification (so that introns are embedded in their 
original location) warrants the appropiate processing 
by the cellular splicing machinery. Considering all this 
information, we decided to use several strategies in 
order to include at least one intron (either the original 
or synthetic) in the expression constructs.  
The final expression vectors were constructed as 
follows. The PDX1 and CDX2/3 vectors were 
generated by insertion of the full-length genomic 
sequences from the ATG to the STOP codons 
(including the corresponding genomic introns) into the 
pcDNA3.1 vector (Invitrogen). The expression vector 
encoding CDX4 was generated by insertion of the 
full-length coding sequence plus genomic intron 2 to 
the pcDNA3 vector. To this end, we used mouse 
genomic DNA as a template to amplify the first exon 
(from the initial ATG to the end of the first exon) and 
fused it to a second amplification product that 
stretched from the beginning of the second exon, 
including intron 2, until the end of the third exon. The 
strategy to clone the coding sequences of CDX1, GSH1 
and GSH2 was as follows: we amplified each single 
coding exon, and subsequently, fused them in-frame; 
the reconstituted full-length cDNA was cloned into 
pcDNA3 and a synthetic intron from pIRESneo (BD 
Biosciences) was additionally cloned after the STOP 
codon at the 3’ UTR of the expression vector.  
A plasmid containing a –645 bp fragment of the 
mouse Insulin II promoter was cloned into the pGL3 
basic vector (Promega) upstream of the luciferase 
reporter gene, using standard cloning methods. This 
promoter segment contains all the necessary and 
sufficient cis-regulatory elements required for the 
correct transcriptional regulation of the insulin gene in 
β-cells [6, 27].  
All the constructs were verified by DNA 
sequencing using the ABI3700 sequencer (AP 
Biosystems). 
Transfections  
Cells grown at about 80% confluence in 
twelve-well plates were transfected using 6 μl of 
Lipofectamine 2000 transfection reagent (Invitrogen 
Life Technologies) following the manufacturer’s 
recommendations with a total of 2.5 μg of DNA, in 
serum-free Optimem medium (Gibco, Invitrogen 
Corporation). For standard transfections, and unless 
otherwise stated, cells were harvested 48 h after 
transfection.  
In all transfections, the quantity of the mouse 
insulin II promoter –645INS-LUC reporter construct 
was maintained constant at 0.5 μg. However, to 
analyse the effect of the overexpression of the ParaHox 
transcription factors, the expression constructs were 
cotransfected in increasing quantities: 0.25 μg, 0.5 μg, 
0.8 μg, 1.2 μg, 1.5 μg, 1.8 μg and 2 μg for the βTC6 cell 
line and at 0.25 μg, 0.5 μg, 0.8 μg, 1.5 μg and 2 μg for 
the αTC1 cell line. The pSV-βGal vector (0.2 μg) was 
also cotransfected to normalise the transfection 
efficiency. For each sample, at least four independently 
replicates were transfected, and duplicate values for 
each replica were obtained. Cells transfected with the 
–645INS-LUC vector but no transcription factor 
construct were used as positive controls and the value 
obtained was considered as the reference unit. Cells 
transfected with empty vectors were considered as 
negative controls. The β-galactosidase and luciferase 
activities were quantified using the ß-Gal Reporter Gene 
Assay chemiluminescent (Roche) and the Luciferase Assay 
Systems E1500 (Promega) kits, respectively, following 
the manufacturer’s recommendations. Each 
luminescence value, the ratio, mean average value and 
the standard deviation were obtained using the FB12 
luminometer (Berthold Detection Systems) and the 
FB12 Sirius SW software (Berthold Detection Systems). 
Statistical significance was assessed by the 
Mann-Whitney test (p<0.05). 
 cDNA obtention and RT-PCR 
Cells were seeded in 12-well plates, transfected 
with 0.8 μg of each ParaHox construct as detailed 
above and grown on high glucose (25 mM) 
supplemented media. Cells (at least three replicates for 
each construct were pooled together) were harvested 
48 hours post-transfection using the “Cells-to-cDNA 
II” kit (Ambion) following the manufacturer’s 
instructions. For each ParaHox transcript, a different 
primer pair spanning different exons was used to 
perform RT-PCR. A housekeeping gene, GAPDH, was 
also amplified to allow normalisation and comparison 
between samples. Primers and PCR conditions are 
detailed in [24], and are available upon request. 
3.  RESULTS 
Constructs controls to assess the effect of ParaHox 
gene overexpression on the insulin promoter 
transactivation 
The construction of the vectors to allow 
constitutive expression of GSH1, GSH2, PDX1, CDX1, 
CDX2/3 and CDX4 in transiently transfected 
eukaryotic cells is detailed in the Material and 
Methods section. In brief, the coding sequence of each Int. J. Biol. Sci. 2008, 4 
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Parahox gene was amplified from mouse genomic 
DNA, from the ATG to the STOP codons and cloned 
into pcDNA3.1. In all the cases, at least one intron 
(either genomic or synthetic) was included in the 
expression constructs. The integrity of the final 
sequence was confirmed by sequencing prior to 
transfection of murine α- and β- pancreatic cells. 
After transfection, the expression levels of each 
Parahox construct were verified by RT-PCR. Cells 
from at least three replicates for each construct and cell 
line were pooled and, total RNA was obtained to 
synthesise the first strand cDNA with a mixture of 
poly-d(T) and random hexamers. Subsequently, the 
cDNA from each Parahox was amplified with specific 
primers from sequences of different exons (Fig. 1). 
GAPDH was used as an internal control. As expected, 
no expression was detected in the reverse transcription 
negative control (–RT lane, Fig.1), whereas we 
amplified the endogenously expressed Pdx1 in β-cells 
transfected with empty-vector (positive control, C lane 
in Fig.1). Much lower, although detectable, levels of 
Pdx1 were also observed in αTC1 cells, in agreement 
with microarray expression reports comparing β- and 
α-derived cells [28].  
 
Figure 1. Expression of the ParaHox constructs in αTC1 
and βTC6 cell lines. Cells were transfected with 0.8 μg of the 
construct for each transcription factor, allowed to grow in high 
glucose media (25mM glucose) and harvested 48 hours 
post-transfections. Cells were harvested from at least three 
replicates and two different experiments for each construct, and 
pooled to obtain the first strand cDNA. Specific primers and 
PCR conditions allowed the detection of each ParaHox gene 
expression. GAPDH was used as an internal control. –RT: 
transfected cells with the Pdx1 transcription factor, but in which 
no reverse transcription was performed (negative control of the 
RT-PCR, as there is no amplification if no cDNA is previously 
obtained). C: empty vector transfected cells, which also serve as 
positive control of the RT-PCR, as Pdx1 is endogenously 
expressed (at low levels in αTC1 cells and at much higher levels 
in βTC6 cells, as expected). 
To assess the effect of the overexpression of the 
ParaHox genes on the insulin promoter activity, we 
relied on the highly sensitive luciferase reporter gene. 
The proximal mice genomic region upstream of the 
insulin transcriptional start site (around 400 bp) had 
already been shown to contain all the regulatory 
elements necessary to confer glucose-dependent 
regulation in cultured β-cell derived lines [29]. Hence, 
we cloned the proximal 645 bp – a slightly larger 
region than strictly required – from this promoter to 
drive the luciferase gene transcription.   
In order to set up the conditions of transfection 
and overexpression of all the ParaHox constructs, we 
first evaluated the effects of PDX1 on β-cells under 
high glucose concentrations, as it is well known that, 
under these conditions, PDX1 is able to transactivate 
the insulin promoter [30, 31]. To determine the 
post-transfection time needed to observe the effects of 
protein overexpression, we compared the results of 
PDX1 overexpression in the βTC6 cell line at either 24 
h or 48 h post-transfection. As depicted in Fig. 2, the 
results at 48 h agreed consistently with the reported 
effects of PDX1 upon the insulin promoter: at low 
glucose concentration, there is no activation (in fact, 
the excess of PDX1 inhibits very weakly the promoter), 
whereas at high glucose concentration, high 
transactivation levels were robustly detected (more 
than 10 fold), even at low DNA concentration of the 
construct expressing the transcription factor. 
 
Figure 2. Effect of PDX1 overexpression on the insulin 
promoter in the βTC6 cell line at low (0.5 mM) or high (25 mM) 
glucose concentrations at either 24 h or 48 h post-transfection. 
The values on the x axis represent the increasing dose (in μg) of 
the PDX1 expression construct used in the transfections. The y 
axis represent the arbitrary transactivation values of the insulin 
promoter with respect to the positive control (c+), which is 
considered as 1. The standard deviation is also indicated. At 
least four independently transfected replicates of each sample 
were analysed. c+ : positive control (cells transfected with the 
–645INS-LUC construct but no transcription factor). c– : 
negative control (cells transfected with empty vectors). Values 
statistically different from the control by the Mann-Whitney test 
(p<0.05) are indicated by one asterisk. Statistically significant 
values that show a stronger effect of the transcription factor on 
the insulin promoter (at least two-fold or more, or half or less, 
than the positive controls) are indicated by two asterisks. Int. J. Biol. Sci. 2008, 4 
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Taken together, these results confirmed that 
overexpression of exogenous PDX1 greatly enhances 
transcription from the insulin promoter in β-derived 
cells (βTC6 cell line), and show that under our 
conditions, 48 h post-transfection were required to 
elicit an appropriate response to different glucose 
concentrations. Therefore, and in order to compare the 
effects of the overexpression of all the ParaHox genes, 
cells were all similarly treated and harvested at 48 h 
post-transfection.  
Overexpression of ParaHox genes in the βTC6 cell 
line 
To evaluate the role of the ParaHox proteins as 
potential transcriptional regulators of the insulin gene, 
we overexpressed these proteins in βTC6 cell lines and 
monitored the activation of a cotransfected reporter 
plasmid containing the mouse insulin II gene promoter 
(-645 to –1). The activation of the insulin promoter is 
very complex and requires a combination of 
interacting transcription factors specific of endocrine 
pancreas, which are activated or produced under high 
glucose concentration. Transfection on β-cells allowed 
us to test directly the effect of any ParaHox gene in a 
cell environment that provided all the necessary 
partners and transcription machinery, including 
e n d o g e n o u s  l e v e l s  o f  P D X 1 .  I n  t h i s  c o n t e x t ,  o u r  
positive control, to which we have referred all 
transactivation values, is the basal transactivation level 
of the luciferase reporter gene driven by the insulin 
promoter, obtained without the overexpression of any 
transcription factor. The positive value observed for 
this control (c+) showed that the promoter was indeed 
bound and transactivated by endogenous protein 
complexes. 
The effect on the transactivation or inhibition of a 
particular promoter by transcription factors is 
dependent on the amount of transcription factor 
available, particularly when low affinities or 
competition for the binding sites are taken into 
consideration. Although, most of the studies on the 
insulin promoter have been performed at high 
concentrations of transcription factors, we decided to 
test the ParaHox transcription factors in a series of 
increasing amounts, while maintaining constant the 
other of parameters. Therefore, we transfected from 
0.25 micrograms (low amount) to 2 micrograms (high 
amount) of construct to study the effect on the insulin 
gene transcription in a dose dependant manner. The 
trends on the promoter are therefore more easily and 
consistently detected. 
The results are summarised in the histogram 
diagrams of Fig. 3. All experiments were consistently 
replicated, and statistical significance of the observed 
differences was determined using the Mann-Whitney 
test (p<0.05, indicated by one asterisk). In summary, 
GSH1 and GSH2 over expression resulted in inhibition 
of the promoter, more pronounced for GSH2, at high 
glucose concentration (Fig. 3), whereas CDX1 and 
CDX2/3 showed a transactivation effect on the insulin 
promoter. CDX1, which acted in a 
glucose-independent manner, yielded around 2-fold 
increase in activity at the highest concentration of 
protein (Fig. 3). CDX2/3, instead, responded 
differently depending on the glucose concentration. 
While having no statitistically significant effect at low 
glucose levels, it was able to transactivate the insulin 
promoter at high glucose concentration, in accordance 
to previous reports [22, 23]. This effect was particularly 
observed when high amounts of the transcription 
factor construct were transfected (4.4-fold increase). In 
contrast, CDX4, which was also sensitive to glucose 
levels, produced the reverse effect to that of CDX2/3. 
Whereas at a low glucose concentration CDX4 over 
expression did not affect the basal transcription of the 
insulin promoter, at high glucose concentration it 
readily inhibited transcription to nearly null values in 
a transcription factor dose-dependent manner (Fig. 3). 
Overexpression of ParaHox genes in the αTC1 cell 
line 
We next intended to evaluate the effects of the 
over expression of the ParaHox genes on the insulin 
promoter in an α-derived cell line, which, on the one 
hand, is of endocrine origin, close to β-cells, sharing 
many transcriptional pathways and expressing similar 
transcription factors, but which, on the other hand, 
respond differently to glucose concentrations. In this 
respect, other authors have shown that the insulin 
promoter can be activated in α-cells after ectopic 
expression of PDX1 under high glucose conditions, 
thus demonstrating the presence in α-cells of the 
coactivator partners required for the transcriptional 
regulation of the insulin gene [32]. 
The effects of the ParaHox over expression on the 
regulation of the insulin promoter were assessed by 
transient transfections on the αTC1 cell line, similarly 
to those performed in βTC6 cells, and the results are 
summarised in Fig. 4. Overexpression of PDX1 in 
α-cells, at low glucose concentrations, resulted in a 
very low activation of the promoter, and only at high 
doses of the transcription factor construct (Fig. 4), 
while at high glucose concentration, the activation of 
the promoter steadily increased in a dose-dependent 
manner, reaching around 3-fold increase at the highest 
amount of transcription factor construct (Fig. 4). This 
result shows that, in the presence of glucose, PDX1 can 
transactivate the insulin promoter in α-cells, albeit at a Int. J. Biol. Sci. 2008, 4 
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much lower efficiency than in β-cells, in accordance to 
previous reports [32-34]. 
 
 
Figure 3. Effect of ParaHox overexpression (except PDX1) on 
the insulin promoter in the βTC6 cell line at low (0.5 mM) or 
high (25 mM) glucose concentration, 48 h post-transfection. The 
values on the x axis represent the increasing dose (in 
micrograms) of each transcription factor expression construct 
used in the transfections. The y axis represent the arbitrary 
transactivation values of the insulin promoter with respect to the 
positive control (c+), which is considered as 1. c+ : positive 
control (cells transfected with the –645INS-LUC construct but 
no transcription factor). c– : negative control (cells transfected 
with empty vectors). Values statistically different from the 
control by the Mann-Whitney test (p<0.05) are indicated by one 
asterisk. Statistically significant values that show a stronger 
effect of the transcription factor on the insulin promoter (at least 
two-fold or more, or half or less, than the positive controls) are 
indicated by two asterisks. 
 
 
Figure 4. Effect of ParaHox overexpression, including PDX1, 
on the insulin promoter in the αTC1 cell line at low (0.5 mM) or 
high (25 mM) glucose concentrations, 48 h post-transfection. 
The values on the x axis represent the increasing dose (in μg) of 
each transcription factor expression construct used in the 
transfections. The y axis represent the arbitrary transactivation 
values of the insulin promoter with respect to the positive 
control (c+), which is considered as 1. c+: positive control (cells Int. J. Biol. Sci. 2008, 4 
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transfected with the –645INS-LUC construct but no 
transcription factor). c– : negative control (cells transfected with 
empty vectors). Values statistically different from the control by 
the Mann-Whitney test (p<0.05) are indicated by one asterisk. 
Statistically significant values that show a stronger effect of the 
transcription factor on the insulin promoter (at least two-fold or 
more, or half or less, than the positive controls) are indicated by 
two asterisks. 
 
Again, GSH1 and GSH2 effects on the insulin 
promoter were not glucose dependent, and as shown 
for  β-cells, their over expression caused a strong 
inhibition of transcription from the insulin promoter in 
a dose-dependent manner, particularly for GSH1 (Fig. 
4). CDX1 over expression did not result in major 
changes on the insulin promoter activity, though at 
high glucose concentrations and at high concentration 
of transcription factor, it weakly increased the activity 
from the insulin promoter (Fig. 4). Instead, CDX2/3 
over expression inhibited the insulin promoter at low 
glucose concentrations to nearly null values at high 
concentrations of the transcription factor (Fig. 4). 
Interestingly, CDX4 again rendered the most 
unexpected result, as it showed sensitivity to glucose 
concentration and, at high glucose concentration, 
highly transactivated the insulin promoter, reaching 
10-fold the value of the control. This effect was more 
pronounced at lower transcription factor doses. 
Noticeably, the effect of CDX4 over expression in 
β-cells at high glucose concentrations was just the 
reverse, while again not detectable effects were 
observed at low levels of glucose.  
In a more physiological context, given that: i) all 
ParaHox genes are expressed in glucagon-producing α 
cells of the endocrine pancreas, ii) α cells do not 
express insulin and, iii) taking into consideration the 
above results, we suggest that the inhibitory effects of 
GSH1, GSH2 and CDX2/3 may contribute to the 
regulation of the insulin promoter in α cells.  
4.  DISCUSSION 
The over expression of proteins in mammalian 
cells, is highly dependent on mRNA stability and 
nucleocytoplasmic export. In this context, our strategy 
to include either one genomic or synthetic intron in 
each expression construct has guaranteed the over 
expression of the transcription factor, and not merely 
that of its RNA (Figure 1, [25, 26]). We also set the 
conditions to assay the effects of the over expression of 
all ParaHox genes after time-course experiments with 
PDX1. Most probably, the higher response at two days 
was due to the higher time of mRNA production or 
high protein stability, which may accumulate and 
hence, induce a higher transactivation of the reporter 
gene. Besides, high PDX1 production during such a 
period of time may also activate, in a positive feedback 
loop, other interacting transcription factors that 
synergistically act upon the insulin promoter [35, 36], 
thus eliciting a stronger and robust promoter response 
[14]. The fact that the overexpression of one single 
transcription factor, PDX1, is sufficient to transactivate 
the insulin promoter, even when the binding of other 
coactivators are required to promote transcription, 
suggests that PDX1 may be a limiting transactivating 
factor in β cells, consistent with its finely-tuned 
regulation. 
PDX1 was also able to activate the insulin 
promoter in a glucose-dependent manner in α cells, 
indicating that many of the proteins required for 
transactivation and regulation of the insulin promoter 
are shared between α- and β-cells. However, the effect 
was much less pronounced than in β-cells, in 
accordance to previous reports [32-34]. Concerning the 
other the ParaHox genes and comparing the results on 
β and α cells, in general, and not unexpectedly, the 
effects of their overexpression, either inhibiting or 
transactivating, are much more pronounced at high 
glucose concentration. This probably reflects the 
availability of other transcription factors or 
coactivators in these cells that respond to glucose 
concentration, and bind to the insulin promoter. Given 
that all ParaHox genes share a very similar 
homeodomain sequence, and probably bind similar 
sequences, our results are more easily interpreted in 
the view of differences in affinity binding to the target 
site and/or in partner recruitment. 
GSH1 and GSH2 did not appear to affect overtly 
the regulation of the insulin promoter, whereas the 
over expression of CDX proteins resulted in a more 
complex regulation pattern. Overall, GSH2 
overexpression resulted in the inhibition of the 
promoter in β cells, depending on the transcription 
factor dose, but irrespective of glucose concentration. 
This inhibitory effect could be due to GSH2 interfering 
with target recognition by endogenous factors and/or 
sequestering of other endogenous coactivators and 
main transactivators, amongst them, PDX1. In fact, 
homeodomain-containing transcription factors usually 
act by assembling into homo- or hetero-oligomers. 
Different partners would shift recognition and affinity 
among different DNA motifs [14]. A similar inhibitory 
effect was observed when over expressing GSH1 in α 
cells, again irrespective of glucose concentration  
CDX1 over expression did not visibly affect the 
transcription from the insulin promoter in α cells, 
while a two-fold transactivation response was clearly 
detected in β cells, even at low concentration of 
transfected construct, suggesting a conserved ability of 
CDX1 to recognise and bind targets at the insulin Int. J. Biol. Sci. 2008, 4 
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promoter. The weak transactivation effect and the fact 
that it is glucose-independent, points to recruitment of 
glucose-independent, and probably non-synergic, 
transcription factors that are available in β- but not in 
α-cells. 
CDX2/3 over expression rendered a different 
result in α or β cells, depending on glucose 
concentration. In α cells, the insulin promoter was 
clearly inhibited at low glucose concentration, whereas 
it was transactivated in β c e l l s  a t  h i g h  g l u c o s e  
concentration. These findings suggest that CDX2/3 
binds to - specific insulin promoter motifs (in 
accordance to the reported binding to the A-boxes of 
the insulin promoter [22]), resulting in either inhibition 
or transactivation, depending on the recruitment and 
interaction to other transcription factors, which differ 
between these two cell lines. However, the ability to 
bind and transactivate the insulin promoter in β cells at 
high glucose concentration, when compared to that of 
PDX1, is moderate and highly dependent on the 
transcription factor dose, thus pointing to a reduced 
affinity for either the promoter targets or limited 
synergy with other required transcription factors.  
Remarkably, CDX4 elicited a strong and 
completely reverse response compared to that of 
CDX2/3 in the two cell lines, or that of PDX1 in β cells. 
This effect of CDX4 over expression was highly 
dependent on glucose concentration and the cell type. 
In  β cells, and only at high glucose concentrations, 
CDX4 strongly inhibited the insulin promoter to null 
activity. In contrast, CDX4 transactivated very 
efficiently (10 fold) the same promoter in α cells, while 
not affecting it, whatsoever, at low glucose 
concentrations. This effect was more pronounced at 
low doses of the transcription factor. Several scenarios 
would account for these results. First, CDX4 may 
recognise and bind directly one or several targets in 
the insulin promoter. In β cells this binding would 
either prevent the binding of the endogenous 
transactivation factors, disrupt or sequester activating 
proteins or protein complexes essentially required for 
transactivation of the insulin promoter, or recruit 
inhibitory proteins. In this c o n t e x t ,  a s  P D X 1  i s  a  
limiting factor in β cells, oligomerization with excess of 
CDX4 could effectively deplete the PDX1 endogenous 
pools. Conversely, the response that CDX4 elicited in α 
cells, again indicated binding to particular motifs and, 
in this case, recruitment of α-cell specific transcription 
factors or coactivators, thus strongly transactivating 
the insulin promoter. In response to high glucose 
concentration, the transactivation effect of CDX4 over 
expression in α cells reached the same levels of that of 
PDX1 in β cells. However, CDX4 showed a saturating 
effect at high transcription factor amounts, which was 
not observed with PDX1.  
In summary, in β cells, no other ParaHox gene 
can substitute efficiently PDX1 on the transactivation 
of the insulin promoter in response to glucose 
concentration, as CDX2/3 was able to do so only at 
high amounts of transcription factor construct, and 
CDX1 transactivated it moderately, but irrespectively 
of glucose levels. Instead, if we consider the results on 
α-cells, CDX4 effectively transactivates the insulin 
promoter, providing a strong response dependent on 
glucose concentration, remarkably similar to that of 
PDX1 in β cells. Our results provide some proof of 
principle that distinct ParaHox transcription factors 
can bind to the same promoter, in this case, the insulin 
promoter, the final transactivating or inhibiting effect 
depending on the strength and affinity to the target 
sites and their interaction with other co-factor partners. 
Consistently, both PDX1 and CDX2 have been shown 
to form heteromeric complexes with PBX1, PDX1 in β 
and δ cells [37, 38], and CDX2, in α cells [21]. The rest 
of ParaHox proteins may also partially share some 
common cofactor networks, targets and responses to 
particular physiological conditions and might well be 
responsible for unaccounted events, such as the few 
insulin producing cells in the Pdx1 knockout. These 
may hold true for other transcription factors belonging 
to the same family and with a conserved homology.  
We are aware that some of these transactivation 
effects of the ParaHox overexpression on the insulin 
promoter in cultured α- or β- cells could be 
non-physiological. For starters, only Pdx1 is 
endogenously expressed in β cells, while the rest of 
ParaHox is endogenously expressed in α cells [24]. 
Nonetheless, on these grounds it is remarkable that 
CDX2/3, GSH1 and GSH2 have strong inhibitory 
effects on the insulin promoter, and thus may 
contribute to the silence of the insulin gene in α cells 
under physiological conditions. 
Finally, given the prevalence of pancreas 
disorders in humans, that all ParaHox genes are 
expressed in adult pancreas and, particularly, the 
results on CDX4 ability to transactivate the insulin 
promoter in α -cells, our data may open new venues to 
explore the physiological role of the ParaHox genes in 
α-cell-based therapy regarding glucose homeostasis.  
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